Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: CoMentis
• Collaborator: Alpharmagen, Inc.

Criteria

Inclusion Criteria:

• Healthy males and females

• Aged 18 to 65 years, inclusive

• Body mass index (BMI) of 18 to 32kg/m^2 inclusive at Screening

• Non-smoker or no tobacco/nicotine usage with 30 days of Screening

Exclusion Criteria:

• Personal or family history of neurological, cardiovascular, renal, hepatic, metabolic, gastrointestinal or endocrine abnormalities

• Any clinical abnormality in cardiovascular (e.g., blood pressure) or electrocardiogram (ECG) parameters at Screening and check-in